Overweight Clinical Trials in Nashville, Tennessee

7 studies are recruiting for overweight in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

    Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Clinical Research Associates - Nashville /ID# 282161, Nashville, Tennessee
    Locations
    45 in total
    Run by
    AbbVie
  2. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

    This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

    Stage
    Phase 3
    Ages
    18 to 79
    Site
    ACCOMPLISH-2 Research Site, Nashville, Tennessee
    Locations
    74 in total
    Run by
    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
  3. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Quality Medical Research, Nashville, Tennessee
    Locations
    56 in total
    Run by
    Eli Lilly and Company
  4. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

    Stage
    Phase 3
    Ages
    6 to 17
    Site
    Vanderbilt Health One Hundred Oaks, Nashville, Tennessee
    Locations
    117 in total
    Run by
    Eli Lilly and Company
  5. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the…

    Stage
    Phase 3
    Ages
    12 to 17
    Site
    Vanderbilt Health One Hundred Oaks, Nashville, Tennessee
    Locations
    34 in total
    Run by
    Eli Lilly and Company
  6. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

    The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    AMR Clinical, Nashville, Tennessee
    Locations
    162 in total
    Run by
    Eli Lilly and Company
  7. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Quality Medical Research, Nashville, Tennessee
    Locations
    40 in total
    Run by
    Eli Lilly and Company

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.